{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-028126","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.183122+00:00","generated_at":"2026-05-16T12:57:37.641017+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Telomir Pharmaceuticals reports favorable GLP safety results for Telomir-1; IND submission targeted Q1 2026","bullets":["No treatment-related adverse or dose-limiting toxicities observed across cardiovascular, respiratory, phototoxicity, and repeat-dose safety studies in rats and dogs.","Telomir-1 well tolerated with consistent systemic exposure; no changes in blood pressure, heart rate, ECG, or body temperature in dogs.","Final quality assurance review ongoing; no findings preclude advancement into first-in-human studies.","Ongoing preclinical studies in triple-negative breast cancer and other age-related diseases; targeting IND submission Q1 2026 and first-in-human H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-028126","json":"https://secwatch.observer/filing/0001493152-25-028126.json","markdown":"https://secwatch.observer/filing/0001493152-25-028126.md","text":"https://secwatch.observer/filing/0001493152-25-028126.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225028126/0001493152-25-028126-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315225028126/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:57:37.641017+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}